---
schema_version: "secwatch.filing_event.v1"
accession: "0001006837-25-000126"
form_type: "8-K"
ticker: "VATE"
cik: "0001006837"
company_name: "INNOVATE Corp."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T20:47:18.905741+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INNOVATE Q3 rev $347M (+43% YoY); net loss narrows to $9.4M; initiates sales processes for DBM Global and Spectrum

## Summary
- Revenue $347.1M, up 43.3% YoY; net loss attributable to common/preferred $9.4M vs $15.3M; EPS -$0.71 vs -$1.18.
- Total Adjusted EBITDA $19.8M (+17.9% YoY). Infrastructure revenue $338.4M (+45.4%); segment Adj. EBITDA $23.5M.
- MediBeacon received NMPA approval to sell Transdermal GFR System in China; expects availability before year-end.
- Missed Sep 1, 2025 debt milestone triggered mandatory sales process for DBM Global; missed Nov 1 milestone for HC2 Broadcasting.
- Adjusted backlog for DBMG $1.6B; added $431M in new awards after Q3. Cash $35.5M at Sep 30 (vs $48.8M year-end 2024).

## SEC filing metadata
- accession: 0001006837-25-000126
- form_type: 8-K
- ticker: VATE
- cik: 0001006837
- company_name: INNOVATE Corp.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006837/000100683725000126/0001006837-25-000126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006837/000100683725000126/vate-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001006837-25-000126
- JSON: https://secwatch.observer/filing/0001006837-25-000126.json
- Plain text: https://secwatch.observer/filing/0001006837-25-000126.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.